Selected research
Market Structure
Global Advanced Biopharmaceutical Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Advanced Biopharmaceutical Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Advanced Biopharmaceutical Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Advanced Biopharmaceutical Therapies include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, AGC Biologics, WuXi AppTec, Charles River Laboratories, Cytiva and Rentschler Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Advanced Biopharmaceutical Therapies market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Advanced Biopharmaceutical Therapies and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Advanced Biopharmaceutical Therapies revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Advanced Biopharmaceutical Therapies market size, projected growth trends, production technologies, key applications, and end-use industries.
Advanced Biopharmaceutical Therapies Segment by Company
Lonza
Thermo Fisher Scientific
Catalent
Samsung Biologics
AGC Biologics
WuXi AppTec
Charles River Laboratories
Cytiva
Rentschler Biopharma
Oxford Biomedica
OmniaBio
Genezen
Cellipont Bioservices
VectorBuilder
Viralgen
ABL Europe
Advanced Biopharmaceutical Therapies Segment by Type
Cell Therapy Services
Gene Therapy Services
Nucleic Acid Therapy Services
Advanced Biopharmaceutical Therapies Segment by Application
Biopharmaceutical Industry
Research and Education Institutions
Others
Advanced Biopharmaceutical Therapies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Advanced Biopharmaceutical Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Advanced Biopharmaceutical Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Advanced Biopharmaceutical Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Advanced Biopharmaceutical Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Advanced Biopharmaceutical Therapies industry.
Chapter 3: Detailed analysis of Advanced Biopharmaceutical Therapies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Advanced Biopharmaceutical Therapiesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Therapy Services
- Gene Therapy Services
- Nucleic Acid Therapy Services
Applications
- Biopharmaceutical Industry
- Research and Education Institutions
- Others
Companies covered
- Lonza
- Thermo Fisher Scientific
- Catalent
- Samsung Biologics
- AGC Biologics
- WuXi AppTec
- Charles River Laboratories
- Cytiva
- Rentschler Biopharma
- Oxford Biomedica
- OmniaBio
- Genezen
- Cellipont Bioservices
- VectorBuilder
- Viralgen
- ABL Europe
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Cell Therapy Services
- 1.2.3 Gene Therapy Services
- 1.2.4 Nucleic Acid Therapy Services
- 1.3 Market Analysis by Application
- 1.3.1 Global Advanced Biopharmaceutical Therapies Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Biopharmaceutical Industry
- 1.3.3 Research and Education Institutions
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Advanced Biopharmaceutical Therapies Growth Trends by Region
- 1.5.1 Global Advanced Biopharmaceutical Therapies Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Advanced Biopharmaceutical Therapies Market Size by Region (2021-2026)
- 1.5.3 Advanced Biopharmaceutical Therapies Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Advanced Biopharmaceutical Therapies Market Dynamics
- 2.1 Advanced Biopharmaceutical Therapies Industry Trends
- 2.2 Advanced Biopharmaceutical Therapies Industry Drivers
- 2.3 Advanced Biopharmaceutical Therapies Industry Opportunities and Challenges
- 2.4 Advanced Biopharmaceutical Therapies Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Advanced Biopharmaceutical Therapies Revenue by Company (2021-2026)
- 3.2 Global Advanced Biopharmaceutical Therapies Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Advanced Biopharmaceutical Therapies Key Company Head office and Area Served
- 3.4 Global Advanced Biopharmaceutical Therapies Company, Product Type & Application
- 3.5 Global Advanced Biopharmaceutical Therapies Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Advanced Biopharmaceutical Therapies Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Advanced Biopharmaceutical Therapies Players Market Share by Revenue in 2025
- 3.6.3 2025 Advanced Biopharmaceutical Therapies Tier 1, Tier 2, and Tier 3
4 Advanced Biopharmaceutical Therapies Market by Type
- 4.1 Global Advanced Biopharmaceutical Therapies Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Advanced Biopharmaceutical Therapies Market Size by Type (2021-2032)
- 4.3 Global Advanced Biopharmaceutical Therapies Market Size Share by Type (2021-2032)
5 Advanced Biopharmaceutical Therapies Market by Application
- 5.1 Global Advanced Biopharmaceutical Therapies Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Advanced Biopharmaceutical Therapies Market Size by Application (2021-2032)
- 5.3 Global Advanced Biopharmaceutical Therapies Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Lonza
- 6.1.1 Lonza Company Information
- 6.1.2 Lonza Business Overview
- 6.1.3 Lonza Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Lonza Advanced Biopharmaceutical Therapies Product Portfolio
- 6.1.5 Lonza Recent Developments
- 6.2 Thermo Fisher Scientific
- 6.2.1 Thermo Fisher Scientific Company Information
- 6.2.2 Thermo Fisher Scientific Business Overview
- 6.2.3 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio
- 6.2.5 Thermo Fisher Scientific Recent Developments
- 6.3 Catalent
- 6.3.1 Catalent Company Information
- 6.3.2 Catalent Business Overview
- 6.3.3 Catalent Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Catalent Advanced Biopharmaceutical Therapies Product Portfolio
- 6.3.5 Catalent Recent Developments
- 6.4 Samsung Biologics
- 6.4.1 Samsung Biologics Company Information
- 6.4.2 Samsung Biologics Business Overview
- 6.4.3 Samsung Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio
- 6.4.5 Samsung Biologics Recent Developments
- 6.5 AGC Biologics
- 6.5.1 AGC Biologics Company Information
- 6.5.2 AGC Biologics Business Overview
- 6.5.3 AGC Biologics Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio
- 6.5.5 AGC Biologics Recent Developments
- 6.6 WuXi AppTec
- 6.6.1 WuXi AppTec Company Information
- 6.6.2 WuXi AppTec Business Overview
- 6.6.3 WuXi AppTec Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio
- 6.6.5 WuXi AppTec Recent Developments
- 6.7 Charles River Laboratories
- 6.7.1 Charles River Laboratories Company Information
- 6.7.2 Charles River Laboratories Business Overview
- 6.7.3 Charles River Laboratories Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio
- 6.7.5 Charles River Laboratories Recent Developments
- 6.8 Cytiva
- 6.8.1 Cytiva Company Information
- 6.8.2 Cytiva Business Overview
- 6.8.3 Cytiva Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Cytiva Advanced Biopharmaceutical Therapies Product Portfolio
- 6.8.5 Cytiva Recent Developments
- 6.9 Rentschler Biopharma
- 6.9.1 Rentschler Biopharma Company Information
- 6.9.2 Rentschler Biopharma Business Overview
- 6.9.3 Rentschler Biopharma Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio
- 6.9.5 Rentschler Biopharma Recent Developments
- 6.10 Oxford Biomedica
- 6.10.1 Oxford Biomedica Company Information
- 6.10.2 Oxford Biomedica Business Overview
- 6.10.3 Oxford Biomedica Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio
- 6.10.5 Oxford Biomedica Recent Developments
- 6.11 OmniaBio
- 6.11.1 OmniaBio Company Information
- 6.11.2 OmniaBio Business Overview
- 6.11.3 OmniaBio Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio
- 6.11.5 OmniaBio Recent Developments
- 6.12 Genezen
- 6.12.1 Genezen Company Information
- 6.12.2 Genezen Business Overview
- 6.12.3 Genezen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Genezen Advanced Biopharmaceutical Therapies Product Portfolio
- 6.12.5 Genezen Recent Developments
- 6.13 Cellipont Bioservices
- 6.13.1 Cellipont Bioservices Company Information
- 6.13.2 Cellipont Bioservices Business Overview
- 6.13.3 Cellipont Bioservices Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio
- 6.13.5 Cellipont Bioservices Recent Developments
- 6.14 VectorBuilder
- 6.14.1 VectorBuilder Company Information
- 6.14.2 VectorBuilder Business Overview
- 6.14.3 VectorBuilder Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio
- 6.14.5 VectorBuilder Recent Developments
- 6.15 Viralgen
- 6.15.1 Viralgen Company Information
- 6.15.2 Viralgen Business Overview
- 6.15.3 Viralgen Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Viralgen Advanced Biopharmaceutical Therapies Product Portfolio
- 6.15.5 Viralgen Recent Developments
- 6.16 ABL Europe
- 6.16.1 ABL Europe Company Information
- 6.16.2 ABL Europe Business Overview
- 6.16.3 ABL Europe Advanced Biopharmaceutical Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio
- 6.16.5 ABL Europe Recent Developments
7 North America
- 7.1 North America Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 7.2 North America Advanced Biopharmaceutical Therapies Market Size by Type
- 7.2.1 North America Advanced Biopharmaceutical Therapies Market Size by Type (2021-2026)
- 7.2.2 North America Advanced Biopharmaceutical Therapies Market Size by Type (2027-2032)
- 7.2.3 North America Advanced Biopharmaceutical Therapies Market Share by Type (2021-2032)
- 7.3 North America Advanced Biopharmaceutical Therapies Market Size by Application
- 7.3.1 North America Advanced Biopharmaceutical Therapies Market Size by Application (2021-2026)
- 7.3.2 North America Advanced Biopharmaceutical Therapies Market Size by Application (2027-2032)
- 7.3.3 North America Advanced Biopharmaceutical Therapies Market Share by Application (2021-2032)
- 7.4 North America Advanced Biopharmaceutical Therapies Market Size by Country
- 7.4.1 North America Advanced Biopharmaceutical Therapies Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 7.4.3 North America Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 7.4.4 North America Advanced Biopharmaceutical Therapies Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 8.2 Europe Advanced Biopharmaceutical Therapies Market Size by Type
- 8.2.1 Europe Advanced Biopharmaceutical Therapies Market Size by Type (2021-2026)
- 8.2.2 Europe Advanced Biopharmaceutical Therapies Market Size by Type (2027-2032)
- 8.2.3 Europe Advanced Biopharmaceutical Therapies Market Share by Type (2021-2032)
- 8.3 Europe Advanced Biopharmaceutical Therapies Market Size by Application
- 8.3.1 Europe Advanced Biopharmaceutical Therapies Market Size by Application (2021-2026)
- 8.3.2 Europe Advanced Biopharmaceutical Therapies Market Size by Application (2027-2032)
- 8.3.3 Europe Advanced Biopharmaceutical Therapies Market Share by Application (2021-2032)
- 8.4 Europe Advanced Biopharmaceutical Therapies Market Size by Country
- 8.4.1 Europe Advanced Biopharmaceutical Therapies Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 8.4.3 Europe Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 8.4.4 Europe Advanced Biopharmaceutical Therapies Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 9.2 China Advanced Biopharmaceutical Therapies Market Size by Type
- 9.2.1 China Advanced Biopharmaceutical Therapies Market Size by Type (2021-2026)
- 9.2.2 China Advanced Biopharmaceutical Therapies Market Size by Type (2027-2032)
- 9.2.3 China Advanced Biopharmaceutical Therapies Market Share by Type (2021-2032)
- 9.3 China Advanced Biopharmaceutical Therapies Market Size by Application
- 9.3.1 China Advanced Biopharmaceutical Therapies Market Size by Application (2021-2026)
- 9.3.2 China Advanced Biopharmaceutical Therapies Market Size by Application (2027-2032)
- 9.3.3 China Advanced Biopharmaceutical Therapies Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 10.2 Asia Advanced Biopharmaceutical Therapies Market Size by Type
- 10.2.1 Asia Advanced Biopharmaceutical Therapies Market Size by Type (2021-2026)
- 10.2.2 Asia Advanced Biopharmaceutical Therapies Market Size by Type (2027-2032)
- 10.2.3 Asia Advanced Biopharmaceutical Therapies Market Share by Type (2021-2032)
- 10.3 Asia Advanced Biopharmaceutical Therapies Market Size by Application
- 10.3.1 Asia Advanced Biopharmaceutical Therapies Market Size by Application (2021-2026)
- 10.3.2 Asia Advanced Biopharmaceutical Therapies Market Size by Application (2027-2032)
- 10.3.3 Asia Advanced Biopharmaceutical Therapies Market Share by Application (2021-2032)
- 10.4 Asia Advanced Biopharmaceutical Therapies Market Size by Country
- 10.4.1 Asia Advanced Biopharmaceutical Therapies Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 10.4.3 Asia Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 10.4.4 Asia Advanced Biopharmaceutical Therapies Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Type
- 11.2.1 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Application
- 11.3.1 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country
- 11.4.1 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Advanced Biopharmaceutical Therapies Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst